Phantomics has been selected as a '2023 Hi-Seoul Company' by the Seoul Business Agency (SBA) for its AI-based cardiovascular disease diagnostic technology company. Hi-Seoul Enterprise is a certification program for outstanding SMEs recognized by the Seoul Metropolitan Government and is celebrating its 20th anniversary this year. It identifies SMEs with excellent corporate capabilities and supports their growth.

Appointed companies are determined by evaluating their capabilities such as growth, technology, and overseas expansion through quantitative and qualitative assessments and on-site inspections. In addition to B2B-only support projects, they will receive preferential benefits for participating in various assisted projects, including networking programs between companies in Seoul, support for global expansion, and support for attracting government projects.

Meanwhile, Phantomics has launched 'Myomics', a solution for early diagnosis and prognosis of cardiovascular diseases based on medical images. The company is expanding into overseas markets such as Japan, Taiwan, Thailand, Singapore, Malaysia, and Chile, as well as large general hospitals in Korea. "This recognition will allow us to further enhance our brand positioning and value in the global market," said Kim Pan-ki, CEO of Phantomics.